| __timestamp | Corcept Therapeutics Incorporated | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 22746000000 |
| Thursday, January 1, 2015 | 1361000 | 21536000000 |
| Friday, January 1, 2016 | 2058000 | 21685000000 |
| Sunday, January 1, 2017 | 3554000 | 25354000000 |
| Monday, January 1, 2018 | 5215000 | 27091000000 |
| Tuesday, January 1, 2019 | 5504000 | 27556000000 |
| Wednesday, January 1, 2020 | 5582000 | 28427000000 |
| Friday, January 1, 2021 | 5281000 | 23402000000 |
| Saturday, January 1, 2022 | 5385000 | 24596000000 |
| Sunday, January 1, 2023 | 6481000 | 26553000000 |
| Monday, January 1, 2024 | 27471000000 |
Unleashing insights
In the world of pharmaceuticals, the cost of revenue is a critical metric that reflects a company's efficiency in managing its production expenses. Over the past decade, Johnson & Johnson and Corcept Therapeutics Incorporated have showcased contrasting trajectories in this regard.
From 2014 to 2023, Johnson & Johnson's cost of revenue has seen a steady increase, peaking at approximately $26.6 billion in 2023. This represents a growth of around 17% over the period, highlighting the company's expansive operations and consistent market demand.
In contrast, Corcept Therapeutics has experienced a dramatic rise, with its cost of revenue surging by over 600% from 2014 to 2023. Starting at a modest $882,000 in 2014, it reached nearly $6.5 million in 2023, reflecting the company's rapid growth and increasing market presence.
Cost of Revenue Trends: Johnson & Johnson vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Mesoblast Limited
Cost of Revenue Trends: Johnson & Johnson vs Viridian Therapeutics, Inc.
Cost Insights: Breaking Down AbbVie Inc. and Corcept Therapeutics Incorporated's Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Xenon Pharmaceuticals Inc.
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Agios Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Corcept Therapeutics Incorporated vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Xencor, Inc.
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and MiMedx Group, Inc.